Hepatotoxicity during treatment for multidrug-resistant tuberculosis: Occurrence, management and outcome

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 596-603

  Keshavjee, Salmaan ^a,b,c   Gelmanova, I Y ^c   Shin, S S ^b,c   Mishustin, S P ^d   Andreev, Y G ^e   Atwood, S ^b   Furin, J J ^f   Miller, A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PARTNERS IN HEALTH   (United States)

^d Tomsk Oblast Tuberculosis Services   (Russian Federation)

^e Federal Penitentiary Services   (Russian Federation)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Drug resistant tuberculosis; Hepatitis; Hepatotoxicity; MDR TB; Russia; Tomsk

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMINOSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ALCOHOL CONSUMPTION; ARTICLE; DRUG WITHDRAWAL; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORBIDITY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISON; RETROSPECTIVE STUDY; RISK FACTOR; RUSSIAN FEDERATION; SMOKING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRISONERS; RETROSPECTIVE STUDIES; RISK FACTORS; RUSSIA; SMOKING; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84859715658     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0591     Document Type: Article

References (56)

1. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481. (Pubitemid 38210067)
2. Furin J J, Mitnick C D, Shin S S, Bayona J, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655. (Pubitemid 32652155)
3. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384. (Pubitemid 39611587)
4. Törün T, Güngör G, Özmen İ, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377. (Pubitemid 43265148)
5. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
6. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments: rationale for monitoring liver status. Drug Saf 1996; 16: 394-405.
7. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
8. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Resp Crit Care Med 2003; 167: 1472-1777.
9. Tost J R, Vidal R, Caylà J, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005; 9: 534-540. (Pubitemid 40646839)
10. Palmero D J, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-784. (Pubitemid 38747156)
11. Dossing M, Wilcke R, Askgaard D, et al. Liver injury during anti-tuberculosis treatment: an 11 year study. Tubercle Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
12. Mitchell J, Zimmerman H, Ishak K, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181-192.
13. Millard P, Wilcosky T, Reade-Christopher S, et al. Isoniazid-related fatal hepatitis. West J Med 1996; 164: 486-491. (Pubitemid 26250847)
14. Singh J, Aora A, Garg P, et al. Anti-tuberculosis treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-362.
15. McDermott W, Ormond L, Muschenheim C, et al. Pyrazinamide and isoniazid in tuberculosis. Am Rev Tuber 1954; 69: 319-333.
16. Gulliford M, Mackay A, Prowse K. Cholestatic jaundice caused by ethambutol. BMJ 1986; 292: 866. (Pubitemid 16133617)
17. Anonymous. Evaluation of a new anti-tuberculous agent. JAMA 1973; 223: 179-180.
18. Wolfson J, Hooper D. Overview of fluoroquinolone safety. Am J Med 1991; 91 (Suppl 6A): 153S-161S.
19. Berning S, Madsen L, Iseman M, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006-2009.
20. Grassmick B, Lehr V, Sundareson A. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26: 636-638.
21. Stricker B. Drug-induced hepatic injury. 2nd ed. Amsterdam, The Netherlands: Elsevier, 1995: pp 237-247.
22. Pattyn S, Janssens L, Bourland J, et al. Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. Int J Lepr Other Mycobact Dis 1984; 52: 1-6. (Pubitemid 14137556)
23. Simpson D, Walker J. Hypersensitivity to para-aminosalicylic acid. Am J Med 1960; 29: 297-306.
24. Zaidi S. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003; 325: 31-33. (Pubitemid 36109686)
25. Ryley N, Fleming K, Chapman R. Focal destructive cholangiopathy associated with amoxicillin-clavulanic acid. J Hepatol 1995; 23: 278-282.
26. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxicillin-clavulanic acid: a report of 15 cases. Gut 1992; 33: 368-371.
27. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
28. Tiwari V. Alcoholic hepatic impairment complicating treatment with hepatotoxic anti-tuberculous medications. J Ind Med Assoc 1996; 94: 347-348. (Pubitemid 27095267)
29. Gronhagen-Riska C, Hellstrom P, Froseth B. Predisposing factors in hepatitis induced by isoniazid and rifampin treatment for tuberculosis. Rev Respir Dis 1978; 118: 461-466. (Pubitemid 9027187)
30. Lee A M, Mennone J Z, Jones R C, Paul W S. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6: 995-1000. (Pubitemid 35408186)
31. Ungo J, Jones D, Ashkin D, et al. Anti-tuberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and HIV. Am J Respir Crit Care Med 1998; 157: 1871-1876.
32. Wong W, Wu P, Yuen M, et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatol 2000; 31: 201-206. (Pubitemid 30033707)
33. Wu J, Lee S, Yeh P, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-504. (Pubitemid 20037938)
34. Pan L, Jia Z, Chen L, et al. Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 2005; 11: 2518-2521. (Pubitemid 40667993)
35. Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36: 293-298. (Pubitemid 36169664)
36. Sadaphal P, Astemborski J, Graham N, et al. Isoniazid preventive therapy, hepatitis C virus infection and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691. (Pubitemid 33044534)
37. Plavinski S L, Plavinskaya S I, Klimov A N. Social factors and increase in mortality in Russia in the 1990s: prospective cohort study. BMJ 2003; 326: 1240-1242. (Pubitemid 36688079)
38. Chenet L, Leon D, McKee M, Vassin S. Deaths from alcohol and violence in Moscow: socio-economic determinants. Eur J Popul 1998; 14: 19-37. (Pubitemid 28441670)
39. Jakubowiak W M, Bogorodskaya E M, Borisov E S, Danilova D I, Kourbatova E K. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007; 11: 46-53. (Pubitemid 46101845)
40. Kimerling M E, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3: 451-453. (Pubitemid 29294697)
41. Kimerling M E, Slavuckij A, Chavers S, et al. The risk of MDRTB and polyresistant tuberculosis among the civilian population of Tomsk City, Siberia, 1999. Int J Tuberc Lung Dis 2003; 7: 866-872. (Pubitemid 37158426)
42. Farmer P E, Furin J J, Shin S S. Managing multidrug-resistant tuberculosis. J Respir Dis 2000; 21: 53-56.
43. Partners In Health. The PIH Guide to the management of m ultidrug-resistant tuberculosis. Boston, MA, USA: Partners In Health/Program in Infectious Disease and Social Change/ Division of Social Medicine and Health Inequalities, Brigham and Woman's Hospital/Harvard Medical School, 2003.
44. Gupta R, Cegielski J P, Espinal M A, et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976. (Pubitemid 35356618)
45. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
46. Tostmann A, Boeree M J, Aarnoutse R E, de Lange W C, van der Ven A J, Dekhuijzen R. Anti-tuberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202. (Pubitemid 351257678)
47. Bender D, Bender A. Nutrition: a reference handbook. Oxford, UK: Oxford University Press, 1997.
48. Laserson K F, Thorpe L E, Lemaine V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
49. Katikova O I, Kostin I V, Tishkin V S. [Hepatoprotective effect of plant preparations]. Eksp Klin Farmakol 2002; 65: 41-43. [Russian]
50. Khvorostinka V M, Il'chenko I A, Bobronnikova L R. [Variations of treatment of chronic alcohol diffusion liver disease]. Lik Sprava 2001; (3): 154-155. [Ukrainian]
51. Watkins P B. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 1-5. (Pubitemid 40216797)
52. Singh J, Garg P, Tandon R. Hepatotoxicity due to anti-tuberculous therapy: clinical profile and reintroduction of therapy. J Clin Gastroenter 1996; 22: 211-214. (Pubitemid 26118626)
53. Tahaoǧlu K, Ataç G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69. (Pubitemid 32401878)
54. Gelmanova I Y, Taran D V, Mishustin S P, Golubkov A A, Solovyova A V, Keshavjee S. 'Sputnik': a programmatic approach for improving tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis 2011; 15: 1373-1379.
55. Alcaide J, Altet M N, Plans P, et al. Cigarette smoking as a risk factor for tuberculosis in young adults: a case control study. Tubercle Lung Dis 1996; 7: 112-116. (Pubitemid 26139142)
56. Silva D R, Menegotto D M, Shultz L F, Gazzana M B, Dalcin P D. Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung 2010; 188: 33-41.